AAM
ICPT

Azzad Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Azzad Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,822
Closed -$221K – 294
2017
Q2 		$221K Buy
+1,822
New +$211K 0.08% 280

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Azzad Asset Management's ICPT Position: Q3 2017 in Review

Azzad Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 1,822 shares — an estimated $221K sold.

Azzad Asset Management first reported a position in ICPT in Q2 2017 and held it in 1 quarter. The position peaked at $221K in Q2 2017. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

  • Azzad Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Azzad Asset Management sold 1,822 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $221K.
  • Azzad Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Azzad Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $221K in Q2 2017.
  • 155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on Azzad Asset Management's 13F filing for Q3 2017, filed 3 Apr 2024.